FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Prostate Cancer
Study : Use of cannabis for cancer symptom management
Most relevant for: People with cancer interested in using cannabis to help manage symptoms.
Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)
Read More
Relevance: Medium
Research Timeline: Post Approval
Update : News from the FDA: First-line treatment and biosimilars for prostate cancer
Relevance: Medium
Research Timeline: Post Approval
Most relevant for: People with prostate cancer
The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)
Este artículo está disponible en español.
Read More
Topic : Acupressure for cancer symptom relief
Most relevant for: People diagnosed with cancer
Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced HER2-positive cancer
The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)
Este artículo está disponible en español.
Read More
Topic : Experts call for early palliative care for cancer patients
Most relevant for: Cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Genetic testing among people with cancer can find mutations that may affect treatment and prevention
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People diagnosed with cancer who have not yet had genetic testing
Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Genes linked to aggressive prostate cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People diagnosed with advanced prostate cancer
Previous research has linked some inherited mutations to prostate cancer risk. This study found a link to additional genes that should be added to prostate cancer gene panel tests. The study also looked at which genes were most closely linked to aggressive prostate cancer that is more likely to spread. (Posted 2/1/24)
Este artículo está disponible en español.
Read More
Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Read More
Update : New first-line treatment option for metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Read More
Relevance: High
Quality of Writing: Medium-High
Article : Genetic testing and the future of medicine
Relevance: High
Quality of Writing: Medium-High
Most relevant for: People interested in genetic testing.
An article published in Katie Couric Media discusses genetic testing and how it can impact health. The author talked with Dr. Robert Steiner, a doctor who specializes in genetics. He talked about genetic testing and how the results can affect health and change lives. (Posted 9/28/23)
Este artículo está disponible en español.
Read More
Search XRAY studies and Articles
This Portal Sponsored By:
